|Mr. Ahmad Ali Mortazavi||CEO & Director||348k||N/A||1971|
|Mr. Michael Anthony Bretherton ACA, B.A.||Acting Interim CFO & Director||53k||N/A||1955|
|Mr. Jonny Wray Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Alan Whitmore B.Sc., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Sarah Clare||Director of Fin. & Compliance||N/A||N/A||N/A|
|Ms. Stephanie Maley CIPD||Chief People Officer||N/A||N/A||N/A|
|Dr. Laura Roca-Alonso Ph.D.||Chief Bus. Officer||N/A||N/A||N/A|
|Ms. Alison Gallafent||Chief Intellectual Property Officer||N/A||N/A||N/A|
|Mr. Ankit Sharma||Head of Software Engineering||N/A||N/A||N/A|
|Mr. Graham Craggs||Head of Therapeutic Discovery||N/A||N/A||N/A|
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.
e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.